⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻

Download the Newsletter Here:

Sexsomnia Newsletter

⸻

Good evening.

Today we will discuss a rare and often misunderstood parasomnia:

Sexsomnia, also known as sleep-related sexual behavior.

This condition lies at the intersection of sleep medicine, neurology, and behavioral science, and has important medical, psychological, and legal implications.

⸻

Definition

Sexsomnia

Sexsomnia is defined as:

• Involuntary sexual behaviors during sleep
• Occurring without conscious awareness
• Typically arising from non-REM sleep

⸻

Classification

Sexsomnia is classified as a:

Non-REM parasomnia

Similar to:

• Sleepwalking
• Sleep terrors

These disorders involve partial arousal from deep sleep

⸻

What Happens During an Episode

During an episode, individuals may:

• Initiate sexual behaviors
• Engage in touching or intercourse
• Vocalize sexually
• Show automatic, goal-directed actions

After the episode:

• No memory of the event
• Confusion if awakened

⸻

Sleep Stage Association

Episodes most commonly arise from:

N3 (deep sleep)

This is the same stage associated with:

• Sleepwalking
• Confusional arousals

⸻

Pathophysiology

Sexsomnia occurs due to:

• Incomplete arousal from deep sleep
• Dissociation between brain regions

Result:

• Motor systems are activated
• Conscious awareness remains suppressed

⸻

Triggers

Common triggers include:

• Sleep deprivation
• Stress
• Alcohol or sedatives
• Irregular sleep schedule

⸻

Associated Conditions

Sexsomnia is often associated with:

• Obstructive Sleep Apnea
• Sleepwalking
• Insomnia Disorder

Fragmented sleep increases risk of parasomnias.

⸻

Clinical Presentation

Patients are often unaware.

Reports usually come from:

• Bed partners
• Family members

Features include:

• Recurrent episodes
• Automatic behavior
• Amnesia for the event

⸻

Why It Happens

The brain is in a mixed state:

• Partially asleep
• Partially awake

This allows:

Complex behaviors without awareness

⸻

Differential Diagnosis

Important to distinguish from:

• Nocturnal seizures
• REM Sleep Behavior Disorder
• Psychiatric conditions

Each has different mechanisms and implications.

⸻

Diagnosis

⸻

Clinical History

• Detailed sleep history
• Witness reports

⸻

Polysomnography (PSG)

May show:

• Arousals from N3
• Associated sleep disorders

Video monitoring is helpful.

⸻

Risks and Implications

Sexsomnia has serious implications:

• Relationship strain
• Emotional distress
• Legal consequences

Consent cannot be established during sleep.

⸻

Treatment

⸻

Address Underlying Causes

• Treat sleep apnea
• Improve sleep quality

⸻

Behavioral Strategies

• Maintain consistent sleep schedule
• Avoid sleep deprivation
• Reduce alcohol use

⸻

Safety Measures

• Separate sleeping arrangements if needed
• Ensure safe environment

⸻

Medications

In selected cases:

• Benzodiazepines
• SSRIs

Used under medical supervision.

⸻

Prognosis

• Often improves with trigger control
• May persist if untreated

Managing underlying sleep disorders is key.

⸻

Key Clinical Insight

Sexsomnia is not intentional behavior.

It is a sleep disorder involving automatic actions without awareness

⸻

Summary

Sexsomnia is:

• A non-REM parasomnia
• Characterized by sexual behaviors during sleep
• Associated with amnesia

Treatment focuses on:

• Reducing triggers
• Improving sleep
• Ensuring safety

⸻

Final Message

Sleep can produce complex behaviors without conscious control.

Understanding sexsomnia is essential to:

• Protect patients
• Support relationships
• Ensure proper medical care

⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻

Insomnia Disorder

⸻

Good evening.

Today we will discuss one of the most common yet misunderstood sleep disorders:

Insomnia Disorder

This is not simply “bad sleep.”

It is a clinical condition that affects brain function, health, and quality of life.

⸻

Definition

Insomnia Disorder

Insomnia Disorder is defined as:

• Difficulty falling asleep
• Difficulty staying asleep
• Waking up too early and unable to return to sleep

Despite having adequate opportunity for sleep

⸻

Diagnostic Criteria

For a clinical diagnosis:

• Occurs at least 3 nights per week
• Persists for ≥ 3 months
• Causes daytime impairment

This distinguishes chronic insomnia from short-term sleep problems.

⸻

Types of Insomnia

⸻

Acute Insomnia

• Short-term
• Triggered by stress or life events
• Lasts days to weeks

⸻

Chronic Insomnia

• Long-term
• Persists ≥ 3 months
• Often maintained by behavioral and physiological factors

⸻

The Sleep System

To understand insomnia, we must understand normal sleep regulation.

Sleep is controlled by:

• Circadian rhythm
• Sleep pressure

In insomnia:

These systems become dysregulated

⸻

Hyperarousal Theory (High Yield)

The most accepted explanation:

Insomnia is a state of hyperarousal

This includes:

• Increased brain activity
• Elevated cortisol
• Increased sympathetic activation

The brain is too awake to sleep

⸻

What Happens in the Brain

In insomnia:

• Increased metabolic activity
• Reduced sleep drive effectiveness
• Difficulty transitioning into sleep

Even when patients feel exhausted, the brain remains alert.

⸻

Common Causes

⸻

Psychological

• Stress
• Anxiety
• Depression

⸻

Behavioral

• Irregular sleep schedule
• Excessive screen time
• Poor sleep habits

⸻

Medical

• Chronic pain
• Medications
• Other sleep disorders

⸻

The Insomnia Cycle

A key concept:

• Poor sleep → worry about sleep
• Worry → increased arousal
• Arousal → worse sleep

This creates a self-perpetuating cycle

⸻

Symptoms

Nighttime:

• Difficulty falling asleep
• Frequent awakenings
• Early morning awakening

Daytime:

• Fatigue
• Poor concentration
• Irritability
• Mood changes

⸻

Objective vs Subjective Sleep

Important concept:

Patients may perceive worse sleep than measured.

However:

The distress is real and clinically significant.

⸻

Impact on Health

Chronic insomnia is associated with:

Hypertension

Depression

Anxiety disorder

It affects both mental and physical health.

⸻

Sleep Architecture Changes

In insomnia:

• Reduced total sleep time
• Increased awakenings
• Reduced deep sleep
• Altered REM patterns

Sleep becomes fragmented and non-restorative.

⸻

Diagnosis

⸻

Clinical Evaluation

• Sleep history
• Symptom pattern
• Duration

⸻

Sleep Diary

Tracks:

• Sleep timing
• Awakenings
• Patterns over time

⸻

Polysomnography (PSG)

Not always required unless:

Another sleep disorder is suspected

⸻

Differential Diagnosis

Important to rule out:

• Obstructive Sleep Apnea
• Restless Legs Syndrome
• Circadian rhythm disorders

⸻

Treatment

⸻

First-Line: Cognitive Behavioral Therapy

Cognitive Behavioral Therapy for Insomnia

CBT-I includes:

• Stimulus control
• Sleep restriction
• Cognitive restructuring

This is the most effective long-term treatment

⸻

Sleep Hygiene

• Consistent schedule
• Avoid caffeine late
• Limit screen exposure
• Comfortable sleep environment

⸻

Medications

Used when necessary:

• Short-term use
• Sleep aids under supervision

Not first-line for chronic insomnia.

⸻

Why CBT-I Works

It addresses:

• Thoughts about sleep
• Behaviors that maintain insomnia

It breaks the insomnia cycle.

⸻

Prognosis

With proper treatment:

Significant improvement is possible

Without treatment:

Chronic insomnia can persist for years

⸻

Key Clinical Insight

Insomnia is not a lack of sleep opportunity.

It is a dysregulation of the sleep system

⸻

Summary

Insomnia Disorder is:

• Difficulty initiating or maintaining sleep
• With daytime impairment
• Driven by hyperarousal and behavioral factors

Treatment focuses on:

• Behavioral therapy
• Addressing underlying causes

⸻

Final Message

Sleep is a natural process.

In insomnia, the brain interferes with its own ability to sleep.

Understanding and retraining the bran is the key to recovery.

⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻⸻

Insomnia Disorder

⸻

Good evening.

Today we will discuss one of the most common yet misunderstood sleep disorders:

Insomnia Disorder

This is not simply “bad sleep.”

It is a clinical condition that affects brain function, health, and quality of life.

⸻

Definition

Insomnia Disorder

Insomnia Disorder is defined as:

• Difficulty falling asleep
• Difficulty staying asleep
• Waking up too early and unable to return to sleep

Despite having adequate opportunity for sleep

⸻

Diagnostic Criteria

For a clinical diagnosis:

• Occurs at least 3 nights per week
• Persists for ≥ 3 months
• Causes daytime impairment

This distinguishes chronic insomnia from short-term sleep problems.

⸻

Types of Insomnia

⸻

Acute Insomnia

• Short-term
• Triggered by stress or life events
• Lasts days to weeks

⸻

Chronic Insomnia

• Long-term
• Persists ≥ 3 months
• Often maintained by behavioral and physiological factors

⸻

The Sleep System

To understand insomnia, we must understand normal sleep regulation.

Sleep is controlled by:

• Circadian rhythm
• Sleep pressure

In insomnia:

These systems become dysregulated

⸻

Hyperarousal Theory (High Yield)

The most accepted explanation:

Insomnia is a state of hyperarousal

This includes:

• Increased brain activity
• Elevated cortisol
• Increased sympathetic activation

The brain is too awake to sleep

⸻

What Happens in the Brain

In insomnia:

• Increased metabolic activity
• Reduced sleep drive effectiveness
• Difficulty transitioning into sleep

Even when patients feel exhausted, the brain remains alert.

⸻

Common Causes

⸻

Psychological

• Stress
• Anxiety
• Depression

⸻

Behavioral

• Irregular sleep schedule
• Excessive screen time
• Poor sleep habits

⸻

Medical

• Chronic pain
• Medications
• Other sleep disorders

⸻

The Insomnia Cycle

A key concept:

• Poor sleep → worry about sleep
• Worry → increased arousal
• Arousal → worse sleep

This creates a self-perpetuating cycle

⸻

Symptoms

Nighttime:

• Difficulty falling asleep
• Frequent awakenings
• Early morning awakening

Daytime:

• Fatigue
• Poor concentration
• Irritability
• Mood changes

⸻

Objective vs Subjective Sleep

Important concept:

Patients may perceive worse sleep than measured.

However:

The distress is real and clinically significant.

⸻

Impact on Health

Chronic insomnia is associated with:

Hypertension

Depression

Anxiety disorder

It affects both mental and physical health.

⸻

Sleep Architecture Changes

In insomnia:

• Reduced total sleep time
• Increased awakenings
• Reduced deep sleep
• Altered REM patterns

Sleep becomes fragmented and non-restorative.

⸻

Diagnosis

⸻

Clinical Evaluation

• Sleep history
• Symptom pattern
• Duration

⸻

Sleep Diary

Tracks:

• Sleep timing
• Awakenings
• Patterns over time

⸻

Polysomnography (PSG)

Not always required unless:

Another sleep disorder is suspected

⸻

Differential Diagnosis

Important to rule out:

• Obstructive Sleep Apnea
• Restless Legs Syndrome
• Circadian rhythm disorders

⸻

Treatment

⸻

First-Line: Cognitive Behavioral Therapy

Cognitive Behavioral Therapy for Insomnia

CBT-I includes:

• Stimulus control
• Sleep restriction
• Cognitive restructuring

This is the most effective long-term treatment

⸻

Sleep Hygiene

• Consistent schedule
• Avoid caffeine late
• Limit screen exposure
• Comfortable sleep environment

⸻

Medications

Used when necessary:

• Short-term use
• Sleep aids under supervision

Not first-line for chronic insomnia.

⸻

Why CBT-I Works

It addresses:

• Thoughts about sleep
• Behaviors that maintain insomnia

It breaks the insomnia cycle.

⸻

Prognosis

With proper treatment:

Significant improvement is possible

Without treatment:

Chronic insomnia can persist for years

⸻

Key Clinical Insight

Insomnia is not a lack of sleep opportunity.

It is a dysregulation of the sleep system

⸻

Summary

Insomnia Disorder is:

• Difficulty initiating or maintaining sleep
• With daytime impairment
• Driven by hyperarousal and behavioral factors

Treatment focuses on:

• Behavioral therapy
• Addressing underlying causes

⸻

Final Message

Sleep is a natural process.

In insomnia, the brain interferes with its own ability to sleep.

Understanding and retraining the bran is the key to recovery.

⸻

Good evening.

Today we will discuss Kleine–Levin Syndrome, one of the most unusual and rare sleep disorders.

This condition is often referred to as:

“Sleeping Beauty Syndrome”

because of its dramatic presentation of prolonged sleep episodes.

⸻

Definition

Kleine-Levin Syndrome

Kleine–Levin Syndrome (KLS) is characterized by:

• Recurrent episodes of extreme hypersomnia
• Behavioral and cognitive disturbances
• Normal functioning between episodes

⸻

Core Features

During episodes, patients may:

• Sleep 15–20 hours per day
• Be difficult to awaken
• Show confusion when awake

These episodes can last:

Days to weeks

⸻

Episodic Nature

A key feature of KLS:

Symptoms occur in episodes

Between episodes, patients return to baseline normal function

This makes diagnosis challenging.

⸻

Associated Symptoms

During episodes:

• Cognitive slowing
• Memory impairment
• Disorientation
• Apathy

⸻

Behavioral Changes

Patients may exhibit:

• Hyperphagia (excessive eating)
• Hypersexuality (in some cases)
• Irritability
• Social withdrawal

⸻

Pathophysiology

The exact cause is unknown.

However, suspected mechanisms include:

• Hypothalamic dysfunction
• Neurotransmitter imbalance
• Possible autoimmune or inflammatory triggers

⸻

Brain Regions Involved

The hypothalamus plays a key role:

• Regulates sleep
• Controls appetite
• Influences behavior

Dysfunction explains many symptoms.

⸻

Triggers

Episodes may be triggered by:

• Infection
• Stress
• Alcohol use
• Sleep deprivation

In many cases, a viral illness precedes onset.

⸻

Who Is Affected

KLS typically affects:

• Adolescents
• More common in males

Onset is usually in teenage years.

⸻

Clinical Presentation

During episodes:

• Prolonged sleep
• Minimal interaction
• Confusion when awake

Between episodes:

Completely normal behavior

⸻

Differential Diagnosis

Important to distinguish from:

• Idiopathic hypersomnia
• Narcolepsy
• Psychiatric disorders
• Depression

KLS is episodic, not chronic.

⸻

Diagnosis

Diagnosis is clinical.

There is no single definitive test.

Evaluation includes:

• History of recurrent episodes
• Exclusion of other disorders
• Sleep studies (often normal between episodes)

⸻

Sleep Study Findings

During episodes:

Increased total sleep time

Between episodes:

Normal sleep architecture

⸻

Treatment

There is no definitive cure.

Management includes:

⸻

Supportive Care

• Ensure safety during episodes
• Monitor nutrition and hydration

⸻

Medications

In some cases:

• Stimulants to reduce sleepiness
• Mood stabilizers

Results are variable.

⸻

Prognosis

KLS is typically:

• Self-limiting
• Episodes decrease over time

Most patients improve over:

8–12 years

⸻

Functional Impact

KLS can significantly affect:

• School performance
• Work
• Social life

Due to unpredictable episodes.

⸻

Key Clinical Insight

KLS is not just excessive sleep.

It is a disorder affecting:

• Sleep
• Behavior
• Cognition

⸻

Summary

Kleine–Levin Syndrome is:

• A rare episodic hypersomnia disorder
• Characterized by prolonged sleep and behavioral changes
• With normal functioning between episodes

⸻

Final Message

KLS is one of the most fascinating sleep disorders.

It demonstrates how deeply sleep is connected to:

• Brain function
• Behavior
• Consciousness

Understanding it helps us better understand the complexity of the human brain.

⸻

KLS Video:

⸻

Author:

Target Audience: Sleep Technologists (RPSGT, CPSGT), Sleep Physicians, ENT Specialists, Primary Care Providers, and Patients considering or using Inspire® therapy.

Introduction: Why Inspire Matters to Everyone in Sleep Medicine

As Inspire® Upper Airway Stimulation (UAS) therapy becomes an increasingly common and effective treatment for Obstructive Sleep Apnea (OSA), a clear understanding of its mechanisms, management, and patient experience is vital. For sleep technologists, Inspire represents a paradigm shift from traditional PAP therapy, demanding a new skill set focused on neurostimulation, precise monitoring, and nuanced documentation. For patients, understanding this innovative therapy is key to making informed decisions and achieving successful outcomes.

This article serves as a comprehensive, multi-faceted guide. It provides RPSGT-focused education on sleep lab workflows, titration studies, and scoring, while also offering essential clinical context for providers and clear, empowering information for patients.

What Is Inspire Therapy?

Inspire® is an implantable therapy for select patients with moderate to severe obstructive sleep apnea (OSA) who cannot tolerate or fail positive airway pressure (PAP) therapy.

It is a form of hypoglossal nerve stimulation (HNS) that:

• Senses the patient’s breathing pattern via a sensing lead (or internally in newer models).
• Delivers mild stimulation, precisely timed to inspiration.
• Activates key upper airway dilator muscles, primarily the genioglossus muscle of the tongue.
• Reduces upper airway collapse and obstruction during sleep.

Important Distinction for Technologists & Patients:

✅ Treats obstructive events

❌ Does not treat central sleep apnea

❌ Does not splint the airway like CPAP; instead, it actively opens the airway from within.

Patient Selection: Who is a Candidate?

Not every patient with OSA is a candidate for Inspire. Understanding the selection criteria is crucial for both clinical teams and prospective patients.

Key Selection Elements (as per FDA labeling and clinical guidelines):

• Moderate to severe obstructive sleep apnea (AHI between 15 and 65 events/hour).
• Documented PAP intolerance or failure.
• Minimal central or mixed apnea burden (typically $<25\%$ of total AHI).
• No complete concentric collapse (CCC) at the soft palate on Drug-Induced Sleep Endoscopy (DISE).
• Acceptable BMI (Body Mass Index) and airway anatomy per current FDA labeling (BMI $\le 40$ in many regions/insurance plans, though this can vary).
• Age $\ge 18$ (with some pediatric exceptions for conditions like Down Syndrome).

💡 Why this matters for Technologists: Residual events during Inspire studies often reflect the patient's underlying phenotype or an unoptimized stimulation setting, rather than poor study quality or scoring.

💡 Why this matters for Patients: Thorough screening ensures the best chance of therapy success and minimizes unnecessary procedures.

Anatomy of Inspire: How it Works

The Inspire system typically consists of two implanted components (though newer models integrate sensing):

1. Stimulation Lead: Placed around the hypoglossal nerve (Cranial Nerve XII), it delivers mild electrical pulses to activate the tongue muscles.
2. Sensing Lead (External or Integrated): Placed between the intercostal muscles of the chest (or integrated into the main device in newer Inspire V models), it detects breathing patterns to synchronize stimulation with inspiration.
3. Implantable Pulse Generator (IPG): A small battery-powered device implanted in the chest, it houses the electronics and battery, receiving signals and delivering stimulation.

Visualizing the System:

Here is a simplified diagram of the Inspire system components and their placement.

Types of Sleep Studies Involving Inspire

Sleep technologists may encounter Inspire patients during several types of studies:

1. Pre-Implant Diagnostic PSG:
   • Standard diagnostic study.
   • Scored per AASM rules.
   • Used to establish baseline severity, event phenotype, and ensure candidacy.
2. Post-Implant Activation (Clinic-Based):
   • Typically performed in the sleep clinic, not the lab.
   • Device is activated and initially programmed weeks after surgery to allow for healing.
3. Inspire Titration PSG (Critical Technologist Role):
   • The primary opportunity for lab-based evaluation and optimization.
   • Focuses on assessing therapy effectiveness and fine-tuning parameters.

Inspire Titration PSG: The Technologist’s Role

This study is where the RPSGT's expertise is paramount.

Purpose of the Study:

• Evaluate the reduction of obstructive events (apneas, hypopneas, RERAs).
• Assess sleep continuity and oxygenation.
• Identify and classify residual respiratory events.
• Document patient tolerance, comfort, and any adverse sensations.
• Provide data directly impacting post-study programming decisions.

What Happens During the Study:

• Patient turns Inspire therapy ON using their remote before lights out.
• Crucially: Stimulation parameters (e.g., amplitude, pulse width) are not typically controlled by the technologist during the study. Adjustments are made post-study by the physician based on the technologist's data.
• Newer Systems (Inspire V): The latest Inspire V model integrates the sensing function directly into the IPG, eliminating the need for a separate intercostal sensing lead. Technologists should be aware of this design change.

Key Responsibilities for the Technologist:

• Monitor: Airflow, respiratory effort, SpO₂, and arousals with precision.
• Observe Changes in:
  • Obstructive apneas, hypopneas, and Respiratory Effort Related Arousals (RERAs).
  • Snoring and inspiratory flow limitation patterns.
  • Oxygen desaturation trends and nadir.
• Document:
  • Time therapy initiated and any pauses.
  • Sleep stage–specific therapy response (e.g., efficacy in REM vs. NREM).
  • Positional differences in therapy efficacy (supine vs. non-supine).
  • Arousals related to obstruction versus potential stimulation discomfort.
  • Patient complaints, awakenings, or perceived sensations.
  • Any visible tongue movement.

📌 Important Difference from PAP: You are not titrating pressure — you are meticulously observing and documenting the physiologic response to breath-synchronized neurostimulation.

Scoring Considerations for RPSGTs

AASM Scoring Rules Still Apply:

• Apneas and hypopneas are scored per standard AASM criteria.
• Inspire therapy does not alter AASM scoring definitions.

Nuances Commonly Seen:

• Residual hypopneas may persist despite otherwise effective therapy, often reflecting subtle airway resistance rather than complete collapse.
• Persistent REM-related obstruction: REM sleep's heightened muscle atonia can challenge therapy, leading to more events during this stage.
• Positional variability: Efficacy may differ significantly between supine and non-supine positions.
• Flow limitation patterns: Airflow may change from a "flattened" morphology to a more rounded, but still dynamic, pattern rather than disappearing completely.
• Central Events: Central apneas may become more visible or even slightly increase once obstructive burden is removed. Accurate classification is essential.

Visualizing Airflow Patterns:

The airflow signal with Inspire therapy can look different from both untreated OSA and optimal CPAP.

• Untreated OSA: Characterized by significant inspiratory flow limitation (flattened inspiratory curve), snoring, desaturations, and often RERAs with associated arousals.
• Inspire Therapy (Breath-Synchronized Stimulation): The green bars indicate stimulation synchronized with inspiration, actively opening the airway. The blue line shows improved, more rounded airflow. Hypoglossal nerve activity (red line) shows the response to stimulation.
• What a Tech Sees (Scored Events): Despite therapy, some residual events like hypopneas or RERAs can still occur. The tech's role is to accurately identify and score these according to AASM guidelines, noting oxygen desaturations and associated EEG arousals.

Sleep Architecture and Inspire Therapy

Common observations include:

• Improved sleep continuity and reduced fragmentation once obstruction is managed.
• Reduced respiratory-related arousals (RERAs).
• Variable REM response that is highly patient-specific.
• Occasional stimulation-related microarousals, especially early in therapy or if amplitude is unoptimized. These should be objectively documented.

Patient Comfort & Safety: What to Document

Common Observations:

• Visible tongue movement or mild stimulation sensation (expected).
• Brief awakenings related to initial stimulation (often resolve with adaptation).
• Minor adjustment effects during the night as patients habituate.

Important to Report:

• Persistent awakenings linked to stimulation that disrupt sleep.
• Significant discomfort (e.g., pain, burning, excessive tongue movement).
• Inability to tolerate therapy overnight (document reason and duration).
• Any speech or swallowing complaints during the study if the patient is awake.

Technologist documentation plays a direct role in post-study programming decisions, informing the physician on amplitude adjustments, ramp times, and other therapy settings.

Troubleshooting Guide for Sleep Technologists

Here’s a quick reference for common issues during an Inspire Titration PSG:

Patient Education Script (For Technologists at Hook-Up)

"Hi , welcome to the sleep lab tonight! My name is , and I'll be your technologist. Tonight, we’ll be doing an Inspire titration study.

• Understanding Tonight: This study helps your doctor see how well your Inspire device is working while you sleep, and if any adjustments are needed. It's really important that your device stays on all night, unless you have a problem.
• Your Remote: Please use your remote to turn your Inspire device ON when you're ready for bed. I’ll make a note of the time.
• What to Expect: You might feel a gentle sensation or see your tongue move slightly when the device is active. This is normal. Your therapy is designed to stimulate your tongue muscles and open your airway with each breath.
• My Role: I'll be monitoring your sleep, breathing, and the device's effects from the control room. I won't be changing your device settings tonight – that's your doctor's job after they review the study. My job is to document everything accurately so they have the best information.
• If You Need Me: If you have any significant discomfort, can't sleep, or need help with anything, just let me know through the intercom. We want you to be as comfortable as possible.
• The Morning: We’ll talk about how you felt and your experience with the device in the morning.

Do you have any questions for me before we get started?"

How Inspire Outcomes Are Evaluated

Both objective and subjective measures are crucial for assessing therapy success.

Objective Measures:

• Reduction in AHI (Apnea-Hypopnea Index) to below a clinical threshold (e.g., <15 or <10 events/hour).
• Improvement in ODI (Oxygen Desaturation Index) and SpO₂ nadir.
• Reduced time spent in obstructive events and associated desaturations.

Subjective Measures:

• Patient-reported sleep quality and daytime alertness (e.g., Epworth Sleepiness Scale - ESS).
• Improved tolerance compared to prior PAP therapy.
• Reduction in snoring and witnessed apneas by a bed partner.

Accurate scoring and documentation by the technologist are foundational to these assessments.

Clinical Evidence: The ADHERE Registry

The ADHERE registry is the largest and longest-running post-market surveillance study for hypoglossal nerve stimulation. It provides real-world evidence of Inspire therapy's effectiveness and safety.

Key Findings from ADHERE (Illustrative Data):

• Significant AHI Reduction: Patients in the ADHERE registry consistently show an average AHI reduction of approximately 70-80% from baseline, often decreasing into the mild or normal range.
• Improved ODI: A similar reduction in ODI is observed, indicating improved oxygenation during sleep.
• High Adherence: Therapy adherence is remarkably high, with 80-90% of patients using their device for 4+ hours per night, 6-7 nights per week, a stark contrast to typical PAP adherence rates.
• Sustained Benefit: Benefits are shown to be sustained over multiple years of follow-up.
• Improved QOL: Significant improvements in quality of life metrics, including reduced daytime sleepiness and improved functional outcomes.

This robust real-world data reinforces Inspire's role as an effective, long-term solution for appropriate OSA patients.

Limitations Technologists and Patients Should Understand

• Inspire does not eliminate all respiratory events: Some patients are "partial responders," meaning significant improvement but not complete normalization of AHI.
• Variable Efficacy: Weight changes, sleep position, sleep stage (especially REM), and even alcohol consumption can influence therapy efficacy.
• Ongoing Optimization: Inspire therapy is often a process of ongoing optimization, requiring follow-up and potential programming adjustments. This is expected and normal therapy management, not treatment failure.

Key Takeaways for RPSGTs and Patients

• Inspire is not CPAP — expectations, monitoring, and problem-solving differ significantly.
• Accurate AASM scoring remains essential for all studies.
• Document physiologic response, not assumptions. Your objective observations are invaluable.
• Understand patient phenotype and candidacy to contextualize study findings.
• Your observations directly influence therapy success through informing programming decisions.
• For Patients: Active engagement, consistent device use, and open communication with your clinical team are key to long-term success.

Professional Disclaimer

This content is intended for professional education of sleep technologists and provides general information for patients. It does not replace physician judgment, device-specific protocols, or institutional policies. Inspire® therapy candidacy, programming, and clinical decisions are determined by qualified healthcare providers in accordance with FDA labeling and clinical guidelines.

Additional Images

Here is an image illustrating the patient remote and its basic functions.

Sleep Lab Titration Checklist – RPSGT Focused

Inspire® Upper Airway Stimulation (UAS)

A Practical, RPSGT-Focused Educational Review for Sleep Technologists

1. Why Sleep Technologists Need to Understand Inspire Therapy

As Inspire® Upper Airway Stimulation becomes more widely used, sleep technologists increasingly encounter patients with implanted devices during:

• Diagnostic PSGs
• Titration studies
• Post-implant optimization studies
• Follow-up efficacy testing

Unlike PAP therapy, Inspire therapy requires a different mindset: the technologist is not titrating pressure, but observing physiologic response to neurostimulation, documenting events accurately, and assisting with therapy optimization.

Understanding how Inspire works, how it affects sleep architecture and respiratory events, and how it is evaluated in the lab is essential for accurate scoring and meaningful clinical outcomes.

2. Mechanism of Action (Tech-Level Explanation)

Inspire is a form of hypoglossal nerve stimulation (HNS) designed to prevent upper airway collapse during sleep.

What the device does:

• Senses the patient’s respiratory effort via a sensing lead
• Delivers timed stimulation to the hypoglossal nerve
• Causes tongue protrusion and upper airway dilation during inspiration
• Reduces obstructive apneas, hypopneas, and flow limitation

What it does NOT do:

• It does not treat central sleep apnea
• It does not splint the airway like CPAP
• It does not eliminate the need for proper sleep staging and event scoring

3. Patient Selection (Why Some Patients Respond and Others Don’t)

From a technologist’s perspective, candidate selection explains variability in outcomes.

Key selection factors you should know:

• Moderate to severe obstructive sleep apnea
• PAP intolerance or failure
• Limited central/mixed apnea burden
• No complete concentric collapse (CCC) at the soft palate on DISE
• Acceptable BMI and airway anatomy per current FDA labeling

💡 Why this matters to techs:
If a patient has residual events despite stimulation, this may reflect phenotype limitations, not poor study quality or poor scoring.

4. Inspire Therapy in the Sleep Lab

4.1 Types of Sleep Studies Involving Inspire

Sleep technologists may encounter Inspire patients during:

1. Baseline PSG (pre-implant)

• Standard diagnostic PSG
• Used to establish severity and event phenotype
• Scored using standard AASM rules

1. Post-implant Activation (not usually a PSG)

• Typically performed in clinic
• Device turned on weeks after surgery
• No overnight monitoring at this stage

1. Inspire Titration PSG (key technologist role)

This is where the sleep technologist plays a critical role.

5. Inspire Titration PSG: What the Tech Actually Does

Purpose of the study:

• Optimize stimulation settings
• Assess reduction in obstructive events
• Evaluate sleep quality and comfort
• Identify residual events

During the study:

• The patient uses their Inspire remote to turn therapy ON
• Stimulation amplitude is not controlled by the tech
• Adjustments are made according to protocol (physician/device representative dependent)

Technologist responsibilities:

• Monitor airflow, effort, oxygenation, and arousals
• Observe for:
  • Reduction in obstructive apneas
  • Reduction in hypopneas
  • Decreased snoring and flow limitation
• Document:
  • Sleep stage–specific response
  • Positional effects
  • Arousal patterns
  • Any stimulation-related discomfort or awakenings

📌 Important:
Unlike PAP titrations, you are not chasing a pressure goal. You are evaluating physiologic response.

6. Scoring Considerations for RPSGTs

AASM Scoring Rules Still Apply

• Apneas and hypopneas are scored per standard AASM criteria
• Inspire does not change scoring definitions

Key nuances to watch:

• Residual hypopneas may persist even with effective stimulation
• Flow limitation patterns may change rather than disappear
• REM-related obstruction may respond differently
• Supine vs non-supine differences are common

Central events:

• Central apneas may become more apparent once obstruction is reduced
• Important to clearly classify events correctly

7. Sleep Architecture and Inspire

Technologists often observe:

• Improved sleep continuity
• Reduced arousals related to obstruction
• Variable effects on REM sleep (patient-specific)
• Occasional stimulation-related microarousals early in therapy

These findings should be objectively documented, not assumed to be adverse.

8. Safety and Patient Comfort (What Techs Should Document)

Common observations:

• Tongue movement or mild discomfort
• Transient awakenings related to stimulation
• Adjustment period effects

Rare but important to document:

• Persistent awakenings linked to stimulation
• Speech or swallowing complaints during wake
• Patient inability to tolerate stimulation overnight

Your documentation directly impacts post-study programming decisions.

9. How Inspire Outcomes Are Evaluated

Objective outcomes:

• AHI reduction
• ODI improvement
• SpO₂ nadir improvement
• Reduced time spent with obstruction

Subjective outcomes:

• Patient-reported sleep quality
• Reduced daytime sleepiness (ESS)
• Improved tolerance compared to PAP

Technologists support these outcomes by accurate staging, event scoring, and documentation.

10. Limitations Techs Should Understand

• Inspire does not eliminate all respiratory events
• Some patients remain partial responders
• Weight changes, sleep position, and sleep stage affect efficacy
• Ongoing follow-up and optimization are expected

This is not a failure of therapy — it is part of long-term management.

11. Practical Takeaways for RPSGTs

• Inspire therapy is not CPAP — adjust expectations
• Accurate scoring is critical for clinical decision-making
• Document stimulation effects clearly
• Understand patient phenotype and candidacy
• Your observations directly influence therapy optimization

Recommended Professional Disclaimer (Forum Use)

For Sleep Technologists:
This material is intended for professional education only and does not replace clinical judgment, physician oversight, or device-specific protocols. Inspire® therapy management and programming decisions are made by qualified providers in accordance with FDA labeling and institutional policy.

Final verdict

✔ Highly appropriate for RPSGT education
✔ Lab-focused and operationally relevant
✔ Accurate and aligned with AASM practice
✔ Excellent forum content for techs

🔹 PRE-STUDY CHECK (Before Lights Out)

☐ Confirm patient has Inspire device implanted
☐ Verify device activation date (therapy ON, not first activation night)
☐ Confirm patient brought Inspire remote
☐ Review study order (titration / efficacy / follow-up PSG)
☐ Confirm no CPAP/BiPAP will be used unless ordered
☐ Review prior PSG results (AHI, REM-related events, positional dependency)
☐ Document baseline complaints (sleep quality, discomfort, prior Inspire issues)

🔹 SETUP & SIGNAL QUALITY

☐ Standard PSG montage per AASM
☐ Ensure high-quality airflow (pressure transducer preferred)
☐ Confirm accurate effort belts (important for residual event classification)
☐ Optimize SpO₂ signal
☐ Audio/video recording ON (important for snoring & arousals)

🔹 THERAPY INITIATION

☐ Patient activates Inspire therapy using remote
☐ Document time therapy turned ON
☐ Note any immediate discomfort or awakenings
☐ Confirm therapy remains ON throughout the night unless instructed otherwise

📌 Important:
Technologists do not control stimulation amplitude unless protocol explicitly allows it.

🔹 DURING THE STUDY – WHAT TO MONITOR

☐ Reduction in obstructive apneas
☐ Reduction in hypopneas
☐ Changes in snoring and flow limitation
☐ Oxygen saturation trends
☐ Sleep architecture changes
☐ REM-related obstruction
☐ Positional differences (supine vs non-supine)
☐ Arousals related to:

• Obstruction
• Stimulation discomfort
• Position change

🔹 EVENT SCORING REMINDERS

☐ Score apneas & hypopneas per standard AASM criteria
☐ Inspire therapy does NOT change event definitions
☐ Carefully distinguish:

• Obstructive vs central events
• Residual hypopneas vs arousal-related breathing changes

🔹 PATIENT COMFORT & SAFETY DOCUMENTATION

☐ Tongue movement noted (expected)
☐ Mild discomfort (document severity & frequency)
☐ Persistent awakenings related to stimulation
☐ Patient requests therapy OFF (document reason & time)
☐ Any speech/swallowing complaints during wake

🔹 END OF STUDY DOCUMENTATION

☐ Total sleep time with Inspire ON
☐ AHI overall and by sleep stage
☐ Supine vs non-supine response
☐ REM response
☐ Oxygenation summary
☐ Patient tolerance summary
☐ Key observations for provider programming decisions

2️⃣ Sample CE Build

Inspire® Therapy for Sleep Technologists

Understanding Lab Titration, Scoring, and Clinical Impact

CE Level

Intermediate
Target Audience: RPSGTs, CPSGTs, sleep technologists

Course Description

This continuing education activity provides sleep technologists with a practical understanding of Inspire® Upper Airway Stimulation (UAS) therapy. Emphasis is placed on sleep lab workflows, Inspire titration PSGs, scoring considerations, and the technologist’s role in therapy optimization.

Learning Objectives

Upon completion of this activity, the participant will be able to:

1. Describe the mechanism of action of Inspire® Upper Airway Stimulation
2. Identify appropriate patient selection criteria for Inspire therapy
3. Explain the role of the sleep technologist during Inspire titration PSGs
4. Apply AASM scoring rules accurately in patients using Inspire therapy
5. Recognize common lab findings, limitations, and safety considerations

Educational Content Outline

Module 1: Overview of Inspire Therapy

• What Inspire is and how it works
• How it differs from PAP therapy
• Indications and contraindications

Module 2: Inspire in the Sleep Lab

• Types of studies involving Inspire
• Pre-implant vs post-implant studies
• Inspire titration PSG goals

Module 3: Technologist Responsibilities

• Therapy activation and documentation
• What technologists can and cannot adjust
• Importance of detailed observation

Module 4: Scoring Considerations

• Standard AASM scoring rules
• Residual events and REM/positional effects
• Central events after obstruction improves

Module 5: Safety, Comfort, and Limitations

• Common patient experiences
• When to escalate concerns
• Long-term optimization expectations

Post-Test (Sample – 10 Questions)

1. Inspire therapy primarily treats which type of sleep apnea?
   A. Central
   B. Mixed
   C. Obstructive ✅
   D. Treatment-emergent
2. Which structure is directly stimulated by Inspire therapy?
   A. Phrenic nerve
   B. Hypoglossal nerve ✅
   C. Vagus nerve
   D. Glossopharyngeal nerve
3. During an Inspire titration PSG, the technologist:
   A. Adjusts stimulation amplitude
   B. Adjusts pressure settings
   C. Observes physiologic response ✅
   D. Turns therapy off after REM
4. Inspire therapy changes AASM scoring rules.
   A. True
   B. False ✅
5. Which evaluation is used to rule out complete concentric collapse?
   A. MSLT
   B. CPAP titration
   C. DISE ✅
   D. Actigraphy
6. Residual hypopneas during Inspire therapy:
   A. Always indicate failure
   B. Are common and patient-specific ✅
   C. Should be ignored
   D. Are central by definition
7. Inspire therapy is best described as:
   A. Pneumatic splinting
   B. Surgical airway bypass
   C. Neurostimulation-based therapy ✅
   D. Oxygen therapy
8. Which finding should always be documented?
   A. Tongue movement
   B. Patient discomfort
   C. Arousals
   D. All of the above ✅
9. Inspire therapy eliminates the need for follow-up.
   A. True
   B. False ✅
10. The technologist’s documentation primarily helps:
    A. Billing
    B. Device programming decisions ✅
    C. Marketing
    D. Surgical planning

CE Disclaimer

This educational activity is intended for professional education only and does not replace physician oversight, institutional protocols, or device-specific training. Inspire® therapy management decisions are made by qualified providers.

Sleep-disordered breathing represents one of the most extensively studied pathophysiological phenomena in sleep medicine.
Among these disorders, sleep apnea remains the most clinically significant due to its association with cardiovascular disease, metabolic dysfunction, neurocognitive impairment, and increased mortality.

The purpose of this educational review is to examine:

• The physiological mechanisms underlying different types of sleep apnea

• The standardized scoring methodology used in polysomnography

• The critical role of the Registered Polysomnographic Technologist, or RPSGT, in identifying, classifying, and quantifying respiratory events

• And how the Apnea-Hypopnea Index, or AHI, is derived directly from scorer-based decisions

This review emphasizes that AHI is not an automated outcome, but a metric fundamentally dependent on human clinical judgment.

Physiological Basis of Sleep Apnea

Obstructive Sleep Apnea

Obstructive sleep apnea is caused by recurrent collapse of the upper airway during sleep, despite continued respiratory drive.
Neuromuscular relaxation during sleep reduces pharyngeal dilator muscle tone, resulting in airway narrowing or closure.

From a physiological standpoint:

• The diaphragm and intercostal muscles continue to generate effort

• Negative intrathoracic pressure increases

• Airflow is impeded due to mechanical obstruction

These physiological mechanisms manifest clearly in polysomnographic signals.

Central Sleep Apnea

Central sleep apnea is characterized by transient withdrawal of central respiratory drive.
Unlike obstructive apnea, the issue is not airway patency but neural regulation of breathing.

Central apneas are often associated with:

• Congestive heart failure

• Cerebrovascular disease

• Opioid-induced respiratory depression

• High-altitude periodic breathing

Physiologically, both airflow and respiratory effort cease due to instability in the respiratory control centers.

Mixed Sleep Apnea

Mixed apnea represents a transitional phenotype in which:

• An event begins with absent respiratory effort

• Followed by re-emergence of effort against an obstructed airway

This pattern reflects complex ventilatory control instability combined with upper airway collapsibility.

Operational Definitions and Scoring Criteria

Apnea Identification

According to AASM scoring rules:

• An apnea is defined as a ≥90% reduction in airflow

• Lasting at least 10 seconds

• During sleep

The classification of apnea subtype depends entirely on effort signal interpretation, which is a scorer-dependent process.

Role of the RPSGT in Apnea Classification

The RPSGT is responsible for:

• Evaluating nasal pressure and thermal airflow signals

• Interpreting thoracic and abdominal effort belts

• Distinguishing artifact from true physiological absence of effort

• Determining whether an event is obstructive, central, or mixed

Automated algorithms cannot reliably differentiate subtle effort patterns, paradoxical breathing, or signal artifact — this remains a human task.

Hypopneas and Clinical Judgment

Hypopneas require nuanced scorer interpretation.

Per AASM criteria, hypopneas involve:

• ≥30% airflow reduction

• Duration ≥10 seconds

• Associated with either oxygen desaturation or EEG arousal

RPSGTs must:

• Determine baseline airflow

• Assess signal stability

• Identify associated cortical arousals

• Exclude movement or signal artifact

Small differences in scorer judgment can significantly alter event counts.

AHI: A Scorer-Derived Metric

Definition

The Apnea-Hypopnea Index is calculated as:

Total apneas + total hypopneas ÷ total sleep time (hours)

AHI is therefore not a raw machine output.
It is the final result of hundreds of micro-decisions made by the scorer.

Impact of Scoring Variability

Research has demonstrated that:

• Differences in hypopnea scoring criteria

• Variability in effort interpretation

• Differences in arousal identification

Can shift a patient from:

• Normal to mild sleep apnea

• Mild to moderate

• Or moderate to severe

Thus, the RPSGT’s role directly influences diagnosis, treatment eligibility, and insurance coverage.

Clinical Implications of AHI

AHI thresholds define:

• Disease severity

• Treatment recommendations

• CPAP eligibility

• Surgical candidacy

• Occupational clearance

Because AHI determines medical decision-making, scorer accuracy is a matter of patient safety and ethical responsibility.

Why RPSGT Expertise Is Essential

RPSGTs provide:

• Consistency in scoring methodology

• Clinical reasoning beyond automation

• Recognition of complex breathing patterns

• Protection against misclassification

The reliability of sleep medicine outcomes depends on trained human scorers adhering to standardized guidelines.

Conclusion

Sleep apnea is not merely a breathing disorder — it is a scored diagnosis.
The Apnea-Hypopnea Index is not simply calculated; it is constructed through expert analysis.

RPSGTs serve as the gatekeepers between raw physiological data and clinical interpretation.
Their role ensures that sleep apnea diagnosis is accurate, reproducible, and clinically meaningful.